Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) insider Amy Simon sold 876 shares of the stock in a transaction on Thursday, July 3rd. The shares were sold at an average price of $20.12, for a total value of $17,625.12. Following the completion of the transaction, the insider directly owned 64,864 shares in the company, valued at $1,305,063.68. This trade represents a 1.33% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Amy Simon also recently made the following trade(s):
- On Tuesday, July 1st, Amy Simon sold 374 shares of Beam Therapeutics stock. The shares were sold at an average price of $16.94, for a total value of $6,335.56.
Beam Therapeutics Trading Up 0.7%
Shares of NASDAQ BEAM traded up $0.14 during midday trading on Friday, reaching $20.02. 1,364,708 shares of the company were exchanged, compared to its average volume of 1,514,705. Beam Therapeutics Inc. has a 1 year low of $13.53 and a 1 year high of $35.25. The stock has a fifty day simple moving average of $17.64 and a 200 day simple moving average of $21.95. The stock has a market cap of $2.01 billion, a P/E ratio of -4.34 and a beta of 2.07.
Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($1.24) EPS for the quarter, missing analysts' consensus estimates of ($1.11) by ($0.13). The firm had revenue of $7.47 million during the quarter, compared to analyst estimates of $14.69 million. Beam Therapeutics had a negative net margin of 609.24% and a negative return on equity of 44.24%. Beam Therapeutics's revenue for the quarter was up 1.4% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.21) EPS. As a group, analysts forecast that Beam Therapeutics Inc. will post -4.57 earnings per share for the current year.
Analyst Ratings Changes
Several equities analysts have issued reports on BEAM shares. Jones Trading raised Beam Therapeutics from a "hold" rating to a "buy" rating and set a $34.00 price objective on the stock in a report on Monday, March 10th. Bank of America raised Beam Therapeutics from a "neutral" rating to a "buy" rating and set a $42.00 price objective on the stock in a report on Friday, March 28th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Beam Therapeutics in a report on Wednesday, March 12th. Wedbush reaffirmed an "outperform" rating and set a $57.00 price objective on shares of Beam Therapeutics in a report on Monday, March 10th. Finally, Barclays dropped their price objective on Beam Therapeutics from $31.00 to $25.00 and set an "equal weight" rating on the stock in a report on Wednesday, May 7th. Two investment analysts have rated the stock with a hold rating, eleven have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $48.75.
Check Out Our Latest Research Report on BEAM
Institutional Investors Weigh In On Beam Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of BEAM. Wealthfront Advisers LLC acquired a new position in shares of Beam Therapeutics in the fourth quarter worth $41,000. GF Fund Management CO. LTD. acquired a new position in shares of Beam Therapeutics in the fourth quarter worth $43,000. Sterling Capital Management LLC grew its stake in Beam Therapeutics by 816.0% in the 4th quarter. Sterling Capital Management LLC now owns 2,409 shares of the company's stock worth $60,000 after acquiring an additional 2,146 shares during the period. CWM LLC grew its stake in Beam Therapeutics by 79.8% in the 1st quarter. CWM LLC now owns 2,684 shares of the company's stock worth $52,000 after acquiring an additional 1,191 shares during the period. Finally, Amalgamated Bank grew its stake in Beam Therapeutics by 20.4% in the 1st quarter. Amalgamated Bank now owns 3,153 shares of the company's stock worth $62,000 after acquiring an additional 534 shares during the period. Hedge funds and other institutional investors own 99.68% of the company's stock.
Beam Therapeutics Company Profile
(
Get Free Report)
Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.
See Also
Before you consider Beam Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beam Therapeutics wasn't on the list.
While Beam Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
